title: Advances in emerging drugs for the treatment of neuroblastoma.
abstract: Neuroblastoma is the most common solid extracranial tumor of childhood. Outcome for children with high-risk neuroblastoma remains suboptimal. More than half of children diagnosed with high-risk neuroblastoma either do not respond to conventional therapies or relapse after treatment with dismal prognosis. Areas covered: This paper presents a short review of the state of the art in the current treatment of high-risk neuroblastoma. An updated review of new targeted therapies in this group of patients is also presented. Expert opinion: In order to improve prognosis for high-risk patients there is an urgent need to better understand spatial and temporal heterogeneity and obtain new predictive preclinical models in neuroblastoma. Combination strategies with conventional chemotherapy and/or other targeted therapies may overcome current ALK inhibitors resistance. Improvement of international and transatlantic cooperation to speed clinical trials accrual is needed.
authors.affiliation: a Unidad de Oncologia Pediatrica, Hospital Universitario La Fe , Valencia , Spain.
authors.forename: Pablo
authors.initials: P
authors.lastname: Berlanga
authors.affiliation: a Unidad de Oncologia Pediatrica, Hospital Universitario La Fe , Valencia , Spain.
authors.forename: Adela
authors.initials: A
authors.lastname: Cañete
authors.affiliation: a Unidad de Oncologia Pediatrica, Hospital Universitario La Fe , Valencia , Spain.|b Instituto de Investigación Sanitaria La Fe , Valencia , Spain.
authors.forename: Victoria
authors.initials: V
authors.lastname: Castel
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002648:Child; D015195:Drug Design; D019008:Drug Resistance, Neoplasm; D006801:Humans; D058990:Molecular Targeted Therapy; D009364:Neoplasm Recurrence, Local; D009447:Neuroblastoma / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents
keywords: ALK inhibitors; Neuroblastoma; PI3K/AKT/mTOR inhibitors; chemotherapy; drug development; emerging drugs; high-dose chemotherapy; immunotherapy; radiotherapy; targeted therapies